The $37.50 central target is calculated from four verifiable analyst price targets. Guggenheim's Vamil Divan set a $40 target (lowered from $43 on Oct. 28, 2026); LifeSci Capital's Rami Katkhuda initiated at $40 on July 22, 2026; Lucid Capital Markets' Dev Prasad set $38 on Aug. 20, 2026; and Leerink Partners' Joseph Schwartz set $32 on Sept. 18, 2026. The simple average is $37.50, with a low of $32 and a high of $40. Cantor Fitzgerald initiated coverage with an Overweight rating in October 2026 but did not publish a price target.
The view is notably one-sided: no analyst has a Hold or Sell rating on the shares. Even so, the $8 spread between the lowest and highest targets shows meaningful disagreement about how much of exaluren's potential value should be reflected in the stock today.
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing exaluren, an oral small-molecule "readthrough" agent designed to restore full-length proteins in patients with rare kidney diseases caused by nonsense mutations. Its two lead programs target nonsense mutation Alport syndrome (NMAS) and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD).
At a recent price near $12.68, reaching $37.50 implies roughly 196% upside — a very large required move. The shares have traded between $8.20 and $23.40 over the past year, so even the midpoint of that range sits well below the target. For the target to be reached, the market would need to assign substantial value to clinical data that will not arrive for quarters or years.
The strongest support is scientific and regulatory. Exaluren has received orphan drug designation from the FDA and the European Commission for Alport syndrome, and from U.S. and European regulators for ADPKD. Management describes a global Alport opportunity of roughly 7,000–8,000 patients and a substantially larger ADPKD population. Peer-reviewed preclinical data reportedly show exaluren restores full-length polycystin-1 in cells carrying PKD1 nonsense mutations.
Financially, the company is funded: a $66 million public offering and a June 2026 uplisting to the Nasdaq Capital Market left about $62 million in cash, with management guiding a runway into mid-2028. Eloxx also retains rights to up to roughly $470 million in milestones, plus royalties, from Almirall's development of ZKN-013.
The principal obstacle is that exaluren is still unproven in humans for these indications. The Phase 2b EXACT trial in NMAS was expected to begin in the third quarter of 2026, with initial 16-week data around mid-2027 and final readout by end of 2027. The 52-week EXPRESS study in ADPKD is not expected to dose its first patient until the third quarter of 2027, with topline data in the first half of 2029. Any delay, safety signal, or disappointing efficacy data could sharply compress the stock.
There are also structural risks. A one-for-eleven reverse split in May 2026 reflects earlier pressure on the share price, and a roughly $51 million market capitalization means thin trading and high volatility. As a pre-revenue company, Eloxx has no earnings or cash flow to cushion a setback.
The stock's 52-week range of $8.20 to $23.40 provides the clearest technical frame. The $23.40 prior high is the first major resistance zone above the current price, while $8.20 marks the recent low. A move toward $37.50 would require first reclaiming and holding above $23.40 — itself a large gain from current levels — before the $30 and $40 psychological levels come into view.
Analyst price targets typically reflect a research horizon of roughly 12 months, though no uniform timeline is stated across the four reports used here. The most important upcoming catalysts are clinical: initiation and enrollment of the EXACT Phase 2b study, initial Alport data expected around mid-2027, and the planned ADPKD dosing start in the third quarter of 2027. Investors should also watch quarterly cash burn, any changes to the mid-2028 runway guidance, analyst target revisions, and regulatory communications with the FDA and European authorities.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name such as ELOX, these signals can help traders spot shifting trends and momentum more efficiently than manual screening. Traders use the tool to discover new opportunities, monitor existing positions, and respond to changing price action. Consider exploring the AI Daily Buy/Sell Signals to see how AI can support your market monitoring routine.
Can ELOX reach $37.50? The target is a real, calculable figure — the average of four current analyst price targets spanning $32 to $40 — but it sits nearly three times above the recent price of about $12.68. Reaching it would require investors to price in successful execution across clinical programs whose key data are still months to years away. The supportive case is grounded in a differentiated mechanism, orphan designations, a fortified balance sheet, and a large theoretical patient opportunity. The counterweight is equally clear: exaluren has not yet demonstrated efficacy in these diseases, and clinical-stage biotechs routinely reprice sharply on negative data. The next data readouts, enrollment milestones, and any analyst target changes are the most useful signals to watch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ELOX has been loosely correlated with XBIO. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ELOX jumps, then XBIO could also see price increases.
| Ticker / NAME | Correlation To ELOX | 1D Price Change % | ||
|---|---|---|---|---|
| ELOX | 100% | -7.92% | ||
| XBIO - ELOX | 59% Loosely correlated | +4.05% | ||
| EOCN - ELOX | 57% Loosely correlated | +7.59% | ||
| IMMP - ELOX | 47% Loosely correlated | -6.47% | ||
| ENVB - ELOX | 40% Loosely correlated | -2.08% | ||
| SRPT - ELOX | 36% Loosely correlated | -2.38% | ||
More | ||||